By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
'Everyone in this prison has had family killed or shot' - 2Hezbollah claims right to respond to killing of top commander
- 3From Novice to Master: Dominating a Side interest
- 4Israeli forces kill one person in series of attacks on southern Lebanon
- 5Step by step instructions to Utilize Open Record Rewards for Your Potential benefit
- NASA counts down for first crewed lunar mission in half a century
- Have gravitational waves provided the first hint of primordial black holes born during the Big Bang?
- From Certificate to Dollars: College Majors with Extraordinary Monetary Prizes
- Spain’s Picos de Europa: What to see and do in ‘the world’s most beautiful place’
- FDA updates risk classification for voluntary shredded cheese recall
- Minute Maid’s frozen juice concentrate is ending after 80 years — and so is a certain kind of kitchen ritual
- 7 Heavenly Espressos, One Do You Like?
- Netflix's Eddie Murphy documentary explains 'Saturday Night Live' beef: 'That's why I didn't go back for years'
- Finding Ideal Date Spots for Two or three Encounters
